• In recent days, Stryker has launched the T2 Alpha Humerus Nailing System and begun limited market release of its Mako RPS handheld robotic system for total knee procedures, alongside declaring a quarterly dividend of US$0.88 per share and reporting full-year 2025 sales of US$25.12 billion and net income of US$3.25 billion.
• These additions to Stryker’s orthopaedic and robotics portfolio highlight how the company is widening its surgical ecosystem, potentially deepening hospital integration and reinforcing product stickiness across trauma, joint replacement and fracture care.
• We’ll now examine how the handheld Mako RPS launch may reshape Stryker’s investment narrative around orthopaedic robotics adoption and growth.

Uncover the next big thing with 28 elite penny stocks that balance risk and reward.

Stryker Investment Narrative Recap

To own Stryker, you need to believe in long term procedure growth in orthopaedics and in the company’s ability to turn its robotics and implant ecosystem into sustained revenue and earnings. The T2 Alpha Humerus launch and Mako RPS handheld rollout both reinforce that ecosystem, but do not materially change the near term focus on orthopaedic robotics adoption as a key catalyst or the ongoing risks from supply chain and regulatory headwinds.

Among the recent updates, the limited market release of Mako RPS for Total Knee looks most relevant, because it extends the Mako franchise into a handheld format that could broaden surgeon use cases for robotic assisted knee procedures. For investors watching the robotics catalyst, this may be an important proof point for how Stryker can layer new platforms onto its existing ortho footprint while still managing cost pressures and integration spending.

Yet even as Stryker expands its robotics footprint, investors should be aware that persistent supply chain disruptions and tariff exposure could still...

Stryker's narrative projects $30.4 billion revenue and $5.4 billion earnings by 2028. This requires 8.4% yearly revenue growth and an earnings increase of about $2.5 billion from $2.9 billion today.

Uncover how Stryker's forecasts yield a $424.40 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community span roughly US$347 to US$424 per share, underscoring how far individual views can spread. Against this backdrop, the importance of Stryker’s orthopaedic robotics pipeline as a key growth catalyst, and the ongoing risks from supply chain and regulatory pressures, gives you a clear lens to compare these differing expectations and explore several alternative viewpoints.

Explore 5 other fair value estimates on Stryker - why the stock might be worth as much as 17% more than the current price!

Build Your Own Stryker Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Stryker research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stryker research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stryker's overall financial health at a glance.

No Opportunity In Stryker?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.